EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study

Luigi Francesco Iannone, Marina Romozzi iD, Antonio Russo iD, Gennaro Saporito, Federico De Santis, Raffaele Ornello, Grazia Sances, Gloria Vaghi, Cristina Tassorelli iD, Maria Albanese iD, Simona Guerzoni, Alfonsina Casalena und 11 weitere

European Journal of Neurology · 2024

DOI: 10.1111/ene.16450 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Luigi Francesco Iannone und 22 weiteren Autor:innen. Beteiligte Einrichtung: Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Calcitonin Gene-Related Peptide. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Although there is extensive evidence about the safety of monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP mAbs) in combination with traditional drugs, scarce data are available on the safety of their combination with other mAbs. This study aimed to evaluate the 6‐month effectiveness and tolerability of anti‐CGRP mAbs in combination with other mAbs for different diseases.

Methods

Patients included in the Italian Headache Registry and treated concomitantly with an anti‐CGRP mAb and another mAb were included. Effectiveness outcomes for migraine included reduction from baseline of monthly headache days (MHDs), Migraine Disability Assessment (MIDAS) score, Headache Impact Test‐6 (HIT‐6) scores, and Patients' Global Impression of Change (PGIC) scale. Adverse events (AEs) were recorded.

Results

Thirty‐eight patients were included. In 27 patients (71.1%), the anti‐CGRP mAb was added to a previously ongoing mAb. Nine patients (23.7%) discontinued one of the two mAbs before the end of treatment (seven discontinued the anti‐CGRP mAb and two the other mAb). One patient discontinued for AEs. Anti‐CGRP mAbs were discontinued due to ineffectiveness ( n = 5, 55.5%) and one each (11.1%) for clinical remission and lost to follow‐up. MHDs significantly decreased from baseline to 3 months ( p < 0.0001) and 6 months ( p < 0.001), as did the MIDAS and the HIT‐6 scores at 3 and 6 months ( p < 0.001). For anti‐CGRP mAbs, 27.4% of patients reported PGIC ≥ 5 at 3 months and 48.3% at 6 months. Mild AEs associated with introduction of a second mAb were detected in six patients (15.8%).

Conclusions

In this real‐world study, anti‐CGRP mAbs showed safety and effectiveness when administered concomitantly with other mAbs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCalcitonin Gene-Related PeptideHumansFemaleMaleMiddle AgedAdultProspective StudiesMigraine DisordersCohort StudiesTreatment OutcomeRegistriesAged

Stichwörter der Autor:innen

CGRPmigrainemonoclonal antibodiespharmacokineticpharmacological interactions

Substanzen

Antibodies, MonoclonalCalcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Headache Center, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy.
  • Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

ORCID-Profile: Marina Romozzi, Antonio Russo, Cristina Tassorelli, Maria Albanese

Zitieren

APA

Iannone, L. F., Romozzi, M., Russo, A., Saporito, G., De Santis, F., Ornello, R., Sances, G., Vaghi, G., Tassorelli, C., Albanese, M., Guerzoni, S., Casalena, A., Vollono, C., Calabresi, P., Prudenzano, M. P., Mampreso, E., Volta, G. D., Valente, M. R., Avino, G., …, & Italian Headache Registry (RICe) study group (2024). Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study. European Journal of Neurology. https://doi.org/10.1111/ene.16450

Vancouver

Iannone LF, Romozzi M, Russo A, Saporito G, De Santis F, Ornello R, et al. Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study. European Journal of Neurology. 2024. doi:10.1111/ene.16450

BibTeX
@article{Iannone2024,
  author = {Iannone, Luigi Francesco and Romozzi, Marina and Russo, Antonio and Saporito, Gennaro and De Santis, Federico and Ornello, Raffaele and Sances, Grazia and Vaghi, Gloria and Tassorelli, Cristina and Albanese, Maria and Guerzoni, Simona and Casalena, Alfonsina and Vollono, Catello and Calabresi, Paolo and Prudenzano, Maria Pia and Mampreso, Edoardo and Volta, Giorgio Dalla and Valente, Maria Rosaria and Avino, Gianluca and Chiarugi, Alberto and Sacco, Simona and Pistoia, Francesca and Italian Headache Registry (RICe) study group, Italian Headache Registry (RICe) study group},
  title = {Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16450}
}
Kostenlos starten →